Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Japanese drugmaker Shionogi has entered into an out-licensing agreement on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa, with the UK’s AMR Centre, based in Alderley Park, Cheshire. 23 July 2019
Biotechnology
Acadia Pharmaceuticals saw its shares fall 16% to $21.62 in after-hours trading on Monday, after it released disappointing top-line results from its Phase III ENHANCE study. 23 July 2019
Biotechnology
A new combination therapy for liver cancer has been granted Breakthrough Therapy Designation (BTD) by the US Food and Drug Administration, unlocking expedited development and review by the US regulator. 23 July 2019
Biotechnology
As the global medical lead of the Adcetris (brentuximab vedotin) program for Japanese pharma major Takeda, Thanos Zomas’ job was made easier by Phase III trial results that he describes as “almost unprecedented.” 22 July 2019
Biotechnology
Israeli biotech firm Intec Pharma (Nasdaq: NTEC) saw its market capitalization plummet after it announced top-line data from the company's pivotal Phase III trial (the ACCORDANCE trial). 22 July 2019
Biotechnology
Shares of US biotech firm Durect were up as much as 39% in light pre-market volume today, as it announced a significant collaboration with Gilead Sciences. 22 July 2019
Biotechnology
Belgium’s UCB has won approval from China’s National Medical Product Administration (NMPA) for Cimzia (certolizumab pegol), to treat moderate-to-severe rheumatoid arthritis. 22 July 2019
Biotechnology
Takeda Pharmaceutical today announced top-line results from the VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic Entyvio (vedolizumab). 22 July 2019
Biotechnology
The US Food and Drug Administration (FDA) has approved Otezla (apremilast) 30mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s disease. 20 July 2019
Biotechnology
Johnson & Johnson’s pharma business Janssen has submitted to broaden the European label for Darzalex (daratumumab), for subcutaneous treatment of multiple myeloma. 19 July 2019
Biotechnology
Gilead Sciences (Nasdaq: GILD) today announced today that it has licensed three pre-clinical antiviral programs, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. 19 July 2019
Biotechnology
Cynata Therapeutics has revealed that it has received an indicative, non-binding and conditional proposal from Japan’s Sumitomo Dainippon Pharma regarding a possible acquisition. 19 July 2019
Biotechnology
European life sciences investment firm Medicxi today announces the closing of Medicxi III, a new 400 million-euro ($488 million) fund. This brings the total amount raised by Medicxi in the last three years to over $1 billion. 19 July 2019
Biotechnology
The US Food and Drug Administration has granted rare pediatric disease designation to LM-030, an investigational therapy licensed from Novartis last year and ready to enter into pivotal clinical trials for the treatment of Netherton syndrome by privately-held rare diseases specialist LifeMax Laboratories. 19 July 2019
Biotechnology
USA-based biotech firm MacroGenics has announced that French privately held drugmaker Servier will terminate their collaboration and license agreement entered into seven years ago, with an effective date of January 15, 2020, unless sooner agreed to by the parties. 18 July 2019
Biotechnology
Following on from an acquisition in the immuno-oncology field and a licensing agreement in the NASH space, privately-held pharma major has announced a third deal this month. 18 July 2019
Biotechnology
UK-incorporated specialty pharmaceutical company Mallinckrodt has agreed terms for an R&D collaboration with RNA interference (RNAi) specialist Silence Therapeutics. 18 July 2019
Biotechnology
Following encouraging results from a Phase Ib study in Japan, Bayer, Bristol-Myers Squibb and Ono Pharmaceutical are collaborating on a clinical trial evaluating the combination of the German firm’s kinase inhibitor Stivarga (regorafenib) and anti-PD-1 immune checkpoint inhibitor Opdivo (nivolumab) from B-MS and Ono, in patients with microsatellite-stable metastatic colorectal cancer (MSS mCRC), the most common type of CRC. 18 July 2019
Biotechnology
Germany’s Merck KGaA and the USA-based Broad Institute of MIT and Harvard (Boston, Massachusetts) today announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for use in commercial research and product development. 18 July 2019
Biotechnology
The global advanced therapy medicinal product (ATMP) sector is growing rapidly, with more than 900 developers active in this space, sponsoring 1,060 clinical trials, including 93 Phase III studies. 18 July 2019
All news
Biotechnology
AstraZeneca and Daiichi Sankyo’s breast cancer med Enhertu (trastuzumab deruxtecan) will be included in China’s state-run health insurance scheme from next year, boosting availability at the cost of reduced pricing. 29 November 2024
Biotechnology
Minghui Pharmaceutical has reported encouraging results from a Phase III trial of MH004 (tofacitinib etocomil) in mild to moderate atopic dermatitis (AD). 29 November 2024
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze